Lineage Cell Therapeutics, Inc.
LCTX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000876343
No open-market purchases or sales by Lineage Cell Therapeutics, Inc. insiders were filed in the last 90 days; 131 institutions reported holding it in 13F filings for Q2 2026, worth $152.7M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding Lineage Cell Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 104 | 3 | 106 | +5 |
| Shares | 64.7M | 82.2K | 65.1M | +498.6K (+0.8%) |
| Value | $73.1M | $92.8K | $76.2M | +$3.19M (+4.4%) |
3 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 173,619 | $203.1K | 0.00% |
| 683 Capital Management, LLC | 128,840 | $150.7K | 0.01% |
| Man Group plc | 102,396 | $119.8K | 0.00% |
| Boothbay Fund Management, LLC | 74,094 | $86.7K | 0.00% |
| Mirabella Financial Services LLP | 74,065 | $86.7K | 0.01% |
| Two Sigma Investments, LP | 30,662 | $35.9K | 0.00% |
| Shay Capital LLC | 29,406 | $34.4K | 0.02% |
| Balyasny Asset Management LLC | 23,740 | $27.8K | 0.00% |
| HRT Financial LP | 20,209 | $23.0K | 0.00% |
| Two Sigma Securities, LLC | 17,320 | $20.3K | 0.00% |
| Verition Fund Management LLC | 10,400 | $12.2K | 0.00% |
| Integrated Wealth Concepts LLC | 10,000 | $12.0K | 0.00% |
| Quadrant Private Wealth Management, LLC | 10,000 | $11.7K | 0.00% |
| Belpointe Asset Management LLC | 611 | $715 | 0.00% |
| Coppell Advisory Solutions LLC | 162 | $190 | 0.00% |
| Coppell Advisory Solutions Corp. | 162 | $190 | 0.00% |
| GWM Advisors LLC | 12 | $0 | 0.00% |
Sold out (12)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| XTX Topco Ltd | 72,807 | $82.0K |
| Gsa Capital Partners LLP | 48,628 | $55.0K |
| Public Employees Retirement System of Ohio | 45,623 | $52.0K |
| LMR Partners LLP | 44,733 | $51.0K |
| Principal Financial Group Inc | 14,937 | $17.0K |
| Haverford Trust Co | 13,612 | $15.0K |
| Prelude Capital Management, LLC | 11,465 | $13.0K |
| BNP Paribas Arbitrage, SA | 4,209 | $4.76K |
| Fifth Third Bancorp | 1,420 | $2.00K |
| Trust Co of Vermont | 2,079 | $2.00K |
| Tucker Asset Management LLC | 150 | $207 |
| Investors Asset Management of Georgia Inc | 2 | $0 |
Not filed for Q4 2022 yet (3)
Institutions that held Lineage Cell Therapeutics, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| American Portfolios Advisors | 44,939 | $50.8K |
| Dowling & Yahnke LLC | 32,263 | $36.0K |
| Wipfli Financial Advisors LLC, | 5,000 | $6.00K |